Form: SCHEDULE 13G

Statement of Beneficial Ownership by Certain Investors

November 16, 2026






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock ("Common Stock") outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by Abeona Therapeutics Inc. (the "Issuer") with the Securities and Exchange Commission (the "Commission") on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G



 
TPG GP A, LLC
 
Signature:/s/ Matthew White
Name/Title:Matthew White / Vice President
Date:11/16/2026
 
COULTER, JAMES G
 
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of James G. Coulter (1)
Date:11/16/2026
 
WINKELRIED JON
 
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of Jon Winkelried (2)
Date:11/16/2026

Comments accompanying signature:  (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.